Switch to:
Also traded in: Argentina, Austria, Brazil, Chile, Germany, Hongkong, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.12
AMGN's Cash-to-Debt is ranked lower than
80% of the 959 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. AMGN: 1.12 )
Ranked among companies with meaningful Cash-to-Debt only.
AMGN' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17  Med: 1.02 Max: N/A
Current: 1.12
Equity-to-Asset 0.40
AMGN's Equity-to-Asset is ranked lower than
79% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. AMGN: 0.40 )
Ranked among companies with meaningful Equity-to-Asset only.
AMGN' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.64 Max: 0.85
Current: 0.4
0.33
0.85
Interest Coverage 13.50
AMGN's Interest Coverage is ranked lower than
83% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AMGN: 13.50 )
Ranked among companies with meaningful Interest Coverage only.
AMGN' s Interest Coverage Range Over the Past 10 Years
Min: 5.3  Med: 9.32 Max: 15.52
Current: 13.5
5.3
15.52
Piotroski F-Score: 7
Altman Z-Score: 2.89
Beneish M-Score: -2.51
WACC vs ROIC
10.71%
31.74%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating Margin % 44.69
AMGN's Operating Margin % is ranked higher than
96% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. AMGN: 44.69 )
Ranked among companies with meaningful Operating Margin % only.
AMGN' s Operating Margin % Range Over the Past 10 Years
Min: 26.94  Med: 33.53 Max: 42.6
Current: 44.69
26.94
42.6
Net Margin % 35.46
AMGN's Net Margin % is ranked higher than
94% of the 744 Companies
in the Global Biotechnology industry.

( Industry Median: -85.19 vs. AMGN: 35.46 )
Ranked among companies with meaningful Net Margin % only.
AMGN' s Net Margin % Range Over the Past 10 Years
Min: 21.43  Med: 27.11 Max: 33.59
Current: 35.46
21.43
33.59
ROE % 26.69
AMGN's ROE % is ranked higher than
96% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. AMGN: 26.69 )
Ranked among companies with meaningful ROE % only.
AMGN' s ROE % Range Over the Past 10 Years
Min: 17.14  Med: 21.47 Max: 26.65
Current: 26.69
17.14
26.65
ROA % 10.51
AMGN's ROA % is ranked higher than
91% of the 966 Companies
in the Global Biotechnology industry.

( Industry Median: -30.83 vs. AMGN: 10.51 )
Ranked among companies with meaningful ROA % only.
AMGN' s ROA % Range Over the Past 10 Years
Min: 7.63  Med: 9.57 Max: 12.11
Current: 10.51
7.63
12.11
ROC (Joel Greenblatt) % 151.64
AMGN's ROC (Joel Greenblatt) % is ranked higher than
95% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: -377.35 vs. AMGN: 151.64 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AMGN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 61.87  Med: 82.2 Max: 167.3
Current: 151.64
61.87
167.3
3-Year Revenue Growth Rate 7.70
AMGN's 3-Year Revenue Growth Rate is ranked higher than
56% of the 517 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. AMGN: 7.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AMGN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 5.8  Med: 16.1 Max: 121.7
Current: 7.7
5.8
121.7
3-Year EBITDA Growth Rate 16.80
AMGN's 3-Year EBITDA Growth Rate is ranked higher than
69% of the 559 Companies
in the Global Biotechnology industry.

( Industry Median: 1.40 vs. AMGN: 16.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AMGN' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -1.6  Med: 16.8 Max: 702.6
Current: 16.8
-1.6
702.6
3-Year EPS without NRI Growth Rate 15.50
AMGN's 3-Year EPS without NRI Growth Rate is ranked higher than
70% of the 545 Companies
in the Global Biotechnology industry.

( Industry Median: -2.60 vs. AMGN: 15.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AMGN' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 2.3  Med: 18.7 Max: 124.6
Current: 15.5
2.3
124.6
GuruFocus has detected 3 Warning Signs with Amgen Inc $AMGN.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AMGN's 30-Y Financials

Financials (Next Earnings Date: 2017-10-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

AMGN Guru Trades in Q3 2016

George Soros 3,506 sh (New)
Richard Pzena 1,196 sh (New)
Paul Tudor Jones 21,333 sh (+276.31%)
Jim Simons 1,896,341 sh (+61.19%)
Ken Fisher 102,794 sh (+1.20%)
Keeley Asset Management Corp 1,325 sh (unchged)
John Hussman 900 sh (unchged)
Mairs and Power 9,916 sh (unchged)
David Carlson 460,000 sh (unchged)
Ray Dalio Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
Third Avenue Management 134,226 sh (-1.04%)
John Buckingham 55,692 sh (-1.22%)
Manning & Napier Advisors, Inc 68,495 sh (-1.81%)
Dodge & Cox 40,157 sh (-2.67%)
PRIMECAP Management 26,560,551 sh (-7.24%)
Lee Ainslie 3,630 sh (-7.87%)
Jeremy Grantham 2,399 sh (-14.29%)
Mario Gabelli 22,425 sh (-38.27%)
Joel Greenblatt 269,204 sh (-44.60%)
Vanguard Health Care Fund 2,759,552 sh (-46.83%)
First Eagle Investment 369,976 sh (-60.50%)
Pioneer Investments 1,554 sh (-98.77%)
» More
Q4 2016

AMGN Guru Trades in Q4 2016

David Dreman 1,114 sh (New)
Richard Snow 15,954 sh (New)
Third Avenue Management 210,262 sh (+56.65%)
Lee Ainslie 4,570 sh (+25.90%)
Ken Fisher 123,139 sh (+19.79%)
Joel Greenblatt 311,380 sh (+15.67%)
Richard Pzena 1,372 sh (+14.72%)
Pioneer Investments 1,767 sh (+13.71%)
Jeremy Grantham 2,499 sh (+4.17%)
Manning & Napier Advisors, Inc 71,003 sh (+3.66%)
John Buckingham 55,900 sh (+0.37%)
Martin Whitman 139,400 sh (+14.92%)
Mairs and Power 9,916 sh (unchged)
David Carlson 460,000 sh (unchged)
George Soros Sold Out
Keeley Asset Management Corp Sold Out
First Eagle Investment Sold Out
John Hussman Sold Out
Mario Gabelli 22,020 sh (-1.81%)
Dodge & Cox 39,207 sh (-2.37%)
PRIMECAP Management 24,999,391 sh (-5.88%)
Jim Simons 1,778,645 sh (-6.21%)
Vanguard Health Care Fund 1,845,162 sh (-33.14%)
Paul Tudor Jones 3,700 sh (-82.66%)
» More
Q1 2017

AMGN Guru Trades in Q1 2017

George Soros 2,000 sh (New)
Barrow, Hanley, Mewhinney & Strauss 248 sh (New)
Jeff Auxier 1,300 sh (New)
Steven Cohen 180,000 sh (New)
Caxton Associates 2,500 sh (New)
Ray Dalio 51,460 sh (New)
Pioneer Investments 91,276 sh (+5065.59%)
Richard Snow 52,001 sh (+225.94%)
Paul Tudor Jones 7,832 sh (+111.68%)
Jim Simons 2,413,445 sh (+35.69%)
Joel Greenblatt 397,344 sh (+27.61%)
Manning & Napier Advisors, Inc 74,381 sh (+4.76%)
John Buckingham 56,326 sh (+0.76%)
Third Avenue Management 211,084 sh (+0.39%)
Martin Whitman 176,500 sh (+26.61%)
Steven Cohen 298,500 sh (unchged)
David Carlson 460,000 sh (unchged)
David Dreman Sold Out
Ken Fisher 123,020 sh (-0.10%)
PRIMECAP Management 24,105,794 sh (-3.57%)
Mario Gabelli 21,024 sh (-4.52%)
Richard Pzena 1,297 sh (-5.47%)
Mairs and Power 8,845 sh (-10.80%)
Lee Ainslie 3,780 sh (-17.29%)
Dodge & Cox 32,137 sh (-18.03%)
Jeremy Grantham 2,000 sh (-19.97%)
Vanguard Health Care Fund 526,472 sh (-71.47%)
» More
Q2 2017

AMGN Guru Trades in Q2 2017

First Eagle Investment 412,708 sh (New)
Charles Brandes 45,736 sh (New)
David Dreman 6,049 sh (New)
Lee Ainslie 10,200 sh (+169.84%)
Jeff Auxier 3,300 sh (+153.85%)
Manning & Napier Advisors, Inc 115,170 sh (+54.84%)
Jim Simons 3,400,145 sh (+40.88%)
Caxton Associates 2,800 sh (+12.00%)
Jeremy Grantham 2,200 sh (+10.00%)
Richard Pzena 1,339 sh (+3.24%)
Ken Fisher 126,537 sh (+2.86%)
John Buckingham 57,078 sh (+1.34%)
Martin Whitman 176,500 sh (unchged)
Vanguard Health Care Fund Sold Out
Paul Tudor Jones Sold Out
George Soros Sold Out
Steven Cohen Sold Out
Mario Gabelli 20,967 sh (-0.27%)
Third Avenue Management 210,430 sh (-0.31%)
Barrow, Hanley, Mewhinney & Strauss 247 sh (-0.40%)
Richard Snow 51,626 sh (-0.72%)
Mairs and Power 8,684 sh (-1.82%)
Pioneer Investments 89,176 sh (-2.30%)
Dodge & Cox 31,137 sh (-3.11%)
David Carlson 440,000 sh (-4.35%)
PRIMECAP Management 22,983,948 sh (-4.65%)
Joel Greenblatt 234,284 sh (-41.04%)
Ray Dalio 26,416 sh (-48.67%)
» More
» Details

Insider Trades

Latest Guru Trades with AMGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
First Eagle Investment 2017-06-30 New Buy0.17%$153.02 - $174.07 $ 167.293%412,708
Joel Greenblatt 2017-06-30 Reduce -41.04%0.34%$153.02 - $174.07 $ 167.293%234,284
Third Avenue Management 2017-06-30 Reduce -0.31%$153.02 - $174.07 $ 167.293%210,430
Ken Fisher 2017-06-30 Add 2.86%$153.02 - $174.07 $ 167.293%126,537
Charles Brandes 2017-06-30 New Buy0.12%$153.02 - $174.07 $ 167.293%45,736
Dodge & Cox 2017-06-30 Reduce -3.11%$153.02 - $174.07 $ 167.293%31,137
Mario Gabelli 2017-06-30 Reduce -0.27%$153.02 - $174.07 $ 167.293%20,967
David Dreman 2017-06-30 New Buy0.57%$153.02 - $174.07 $ 167.293%6,049
Richard Pzena 2017-06-30 Add 3.24%$153.02 - $174.07 $ 167.293%1,339
Barrow, Hanley, Mewhinney & Strauss 2017-06-30 Reduce -0.40%$153.02 - $174.07 $ 167.293%247
Vanguard Health Care Fund 2017-06-30 Sold Out 0.19%$153.02 - $174.07 $ 167.293%0
George Soros 2017-06-30 Sold Out 0.01%$153.02 - $174.07 $ 167.293%0
Vanguard Health Care Fund 2017-03-31 Reduce -71.47%0.46%$150.73 - $182.6 $ 167.291%526,472
Joel Greenblatt 2017-03-31 Add 27.61%0.18%$150.73 - $182.6 $ 167.291%397,344
Third Avenue Management 2017-03-31 Add 0.39%0.01%$150.73 - $182.6 $ 167.291%211,084
Ken Fisher 2017-03-31 Reduce -0.10%$150.73 - $182.6 $ 167.291%123,020
Dodge & Cox 2017-03-31 Reduce -18.03%$150.73 - $182.6 $ 167.291%32,137
Mario Gabelli 2017-03-31 Reduce -4.52%$150.73 - $182.6 $ 167.291%21,024
George Soros 2017-03-31 New Buy0.01%$150.73 - $182.6 $ 167.291%2,000
Richard Pzena 2017-03-31 Reduce -5.47%$150.73 - $182.6 $ 167.291%1,297
Barrow, Hanley, Mewhinney & Strauss 2017-03-31 New Buy$150.73 - $182.6 $ 167.291%248
David Dreman 2017-03-31 Sold Out 0.09%$150.73 - $182.6 $ 167.291%0
Martin Whitman 2017-01-31 Add 26.61%0.52%$135.22 - $158.84 $ 167.2913%176,500
Vanguard Health Care Fund 2016-12-31 Reduce -33.14%0.33%$135.22 - $168.31 $ 167.2911%1,845,162
Joel Greenblatt 2016-12-31 Add 15.67%0.08%$135.22 - $168.31 $ 167.2911%311,380
Third Avenue Management 2016-12-31 Add 56.65%0.5%$135.22 - $168.31 $ 167.2911%210,262
Ken Fisher 2016-12-31 Add 19.79%$135.22 - $168.31 $ 167.2911%123,139
Dodge & Cox 2016-12-31 Reduce -2.37%$135.22 - $168.31 $ 167.2911%39,207
Mario Gabelli 2016-12-31 Reduce -1.81%$135.22 - $168.31 $ 167.2911%22,020
Richard Pzena 2016-12-31 Add 14.72%$135.22 - $168.31 $ 167.2911%1,372
David Dreman 2016-12-31 New Buy0.09%$135.22 - $168.31 $ 167.2911%1,114
George Soros 2016-12-31 Sold Out 0.02%$135.22 - $168.31 $ 167.2911%0
First Eagle Investment 2016-12-31 Sold Out 0.16%$135.22 - $168.31 $ 167.2911%0
Keeley Asset Management Corp 2016-12-31 Sold Out 0.01%$135.22 - $168.31 $ 167.2911%0
Martin Whitman 2016-10-31 Add 14.92%0.24%$141.16 - $175.62 $ 167.29-1%139,400
Vanguard Health Care Fund 2016-09-30 Reduce -46.83%0.78%$154.27 - $175.62 $ 167.29-1%2,759,552
First Eagle Investment 2016-09-30 Reduce -60.50%0.22%$154.27 - $175.62 $ 167.29-1%369,976
Joel Greenblatt 2016-09-30 Reduce -44.60%0.4%$154.27 - $175.62 $ 167.29-1%269,204
Third Avenue Management 2016-09-30 Reduce -1.04%0.01%$154.27 - $175.62 $ 167.29-1%134,226
Ken Fisher 2016-09-30 Add 1.20%$154.27 - $175.62 $ 167.29-1%102,794
Dodge & Cox 2016-09-30 Reduce -2.67%$154.27 - $175.62 $ 167.29-1%40,157
Mario Gabelli 2016-09-30 Reduce -38.27%0.02%$154.27 - $175.62 $ 167.29-1%22,425
George Soros 2016-09-30 New Buy0.02%$154.27 - $175.62 $ 167.29-1%3,506
Richard Pzena 2016-09-30 New Buy$154.27 - $175.62 $ 167.29-1%1,196
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:CELG, NAS:GILD, NAS:BIIB, NAS:REGN, NAS:VRTX, NAS:ALXN, NAS:INCY, NAS:BMRN, NAS:EXEL, NAS:ALNY, NAS:KITE, NAS:SGEN, NAS:BIVV, NAS:TSRO, NAS:IONS, NAS:UTHR, NAS:NBIX, NAS:TECH, NAS:BLUE, NAS:ACAD » details
Traded in other countries:AMGN.Argentina, AMGN.Austria, AMGN34.Brazil, AMGN.Chile, AMG.Germany, 04332.Hongkong, AMG N.Mexico, AMGN.Switzerland, 0R0T.UK,
Headquarter Location:USA
Amgen Inc is a U.S. based biotechnology company, with historical expertise in renal disease and cancer supportive care products. The firm discovers, develops, manufactures and delivers human therapeutics.

Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and received approval for bone-strengthening drug Prolia/Xgeva in 2010. Amgen's acquisition of Onyx bolsters the firm's therapeutic oncology portfolio with Nexavar and Kyprolis.

Guru Investment Theses on Amgen Inc

Third Avenue Fund Comments on Amgen - Sep 14, 2016

Livallova

Investor neglect can be a source of new ideas while also providing an element of downside protection. We found this combination to be compelling in our purchase of Livallova (NASDAQ:LIVN), which is the new name for Sorin and Cyberonics post their late-2015 merger. We think investor neglect was paramount, for Sorin, an Italian company, which merged with Cyberonics, based in Houston, changed its name and reincorporated in London. Indeed, we came across the company on a screen of our potential universe of companies, and had to do some digging into the new name we did not recognize, to realize the potential for these two well-known companies and the significant potential their merger offers.

Livallova is a healthcare company with a $3 billion market capitalization that holds leading positions in cardiac surgical equipment, surgical heart valve replacement, neuromodulation and cardiac rhythm management. In its cardiac surgery division, Livallova holds number one positions in Oxygenators and Heart Lung machines. It also is rapidly gaining share with its new sutureless Perceval heart valve, with a history of successful procedures in Europe and recently approved in the U.S. In Neuromodulation, Livallova holds the number one position in devices for the treatment of drug resistant epilepsy, led by its success with its AspireSR device. Livallova is also rapidly gaining share in cardiac rhythm management with Kora250 and Platinium in Japan and Europe, while retaining options on strategies to re-enter the U.S. market. In all, Livallova holds number one positions in over 60% of its revenues.

Livallova also has a strong self-help profile, with targeted synergies from its merger of $80 million over three years. As of its second quarter earnings call, Livallova indicated it was ahead of the first phase of $19 million expected in 2016. Creditworthiness for the company is easily demonstrated by net debt of roughly $75 million.

The ability to compound earnings and book value growth is not only supported by its new product introductions and merger synergies, but also its compelling research and development pipeline, which Livallova refers to as its New Ventures unit. In this unit, Livallova is pursuing groundbreaking new technologies in percutaneous mitral valve repair and replacement, the adaption of its Neuromodulation technologies for treatment of central and obstructive sleep apnea and also the potential to treat heart failure through vagus nerve stimulation. Not only is the potential market opportunity for all three of these areas separately in excess of a billion dollars, but through its merger, Livallova has multiple research efforts in each area to evaluate, streamline and prioritize.

Brexit created a window to initiate a position at under $50 per share for the Fund, which represents a compelling 50% upside to our fair value NAV target. Perhaps due to investor neglect on the name, Livallova trades at a substantial discount to its U.S. peers. We think this discount and its relatively smaller market capitalization also provide downside protection, for the company would likely be attractive to a larger entity looking to expand its product franchise.



From Third Avenue Value Fund's third quarter 2016 letter.



Check out Third Avenue Management,Martin Whitman latest stock trades

Third Avenue Fund Comments on Amgen - Sep 14, 2016

Amgen (NASDAQ:AMGN), which was founded in 1980, is one of the world's leading biotechnology companies. Interestingly, the biotech industry has matured over the years and some of the companies generate stable cash flows, not unlike some of the larger pharmaceutical companies. Amgen is one of these. Competitive issues, largely surrounding the biosimilar debate, have put pressure on Amgen's stock. Post-Brexit market volatility provided us an opportunity to acquire shares.

Amgen has a diversified product portfolio across six therapeutic areas: oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience. Its key products are Enbrel for long-term inflammatory diseases such as rheumatoid arthritis; Epogen and Aranesp for anemia; Neupogen and Neulasta for treating neutropenia (a lack of certain white blood cells caused by cancer, bone marrow transplant, or after chemotherapy). Newer drugs include Repatha, which targets high cholesterol for the roughly 20% of the population who are intolerant of statins (the typical first line treatment), and Kyprolis for multiple myeloma, an incurable bone cancer. Its pipeline consists of 31

preclinical and clinical targets, 12 of which are in the later stages. Amgen also has a pipeline of 9 biosimilars, of which 3 are in late stage and for which the worldwide sales of the originator drugs totaled approximately $54 billion in 2015.

The company generated $9 billion in operating cash flow in 2015, up from $5.1 billion in 2011. The company has used its excess cash flow to fund growth as well as return cash to shareholders via both share buybacks and dividends. It expects to return 60% of adjusted net income to shareholders by 2018.

Amgen has longer-term opportunities for margin improvement from synergies and cost controls. The company initiated a large-scale "transformation" program in 2013 to focus on efficient allocation of resources. The plan included an approximately 23% reduction in its facilities footprint and a 20% reduction in headcount by the end of 2015, with a goal of generating $1.5 billion of annual savings and a 15-point increase in adjusted operating margin by 2018. So far, the company's adjusted operating margin has increased from 38% in 2013 to 48% in 2015 and 55% in 1Q16. Management believes it is on a path to achieve 52-54% by 2018. In addition, the company's new next-generation bio-manufacturing facility is on track. The facility is expected to increase bulk production capabilities at a quarter of capital costs, 1/3 of operating costs and 2x speed vs. conventional facilities, resulting in an estimated cost reduction of 60%+ per gram of protein.

Competitive threats confront any company and even more so for biotech and pharma companies as their products face patent expirations. Biosimilar products are newer to the marketplace and the regulatory pathway is still evolving, with questions of interchangeability with the branded drug still progressing. Biologics are scientifically more challenging than small molecule generic development, more costly to develop and require high-quality complex manufacturing. Price discounting to date has been substantially less than small molecule generics, but may vary over the longer-term. As such, we look to acquire shares at a reasonable estimate of the company's base business without giving much credit to the pipeline. We believe this provides downside protection for the competitive threats while providing opportunity for upside given the growing pipeline. We took advantage of volatility during the quarter to acquire shares of Amgen common at around a 25% discount to our estimate of NAV.



From Third Avenue Value Fund's third quarter 2016 letter.



Check out Third Avenue Management,Martin Whitman latest stock trades

Top Ranked Articles about Amgen Inc

Amgen in Collaboration With Humana for Patients' Benefit The companies will also have a deep focus into specific therapeutic areas
Amgen (AMGN) has informed the market through a news release published on its website that it will collaborate with Humana (HUM) to uncover opportunities for the improvement of patient health outcomes and for the improvement of the health care system’s efficiency. Read more...
Amgen And Humana Partner For Improved Health Outcomes And Efficiency
Repatha® (Evolocumab) Phase 3 Cognitive Function Study Results Published In The New England Journal Of Medicine
Graham Disciple Charles Brandes' 5 Largest 2nd Quarter New Buys Brandes Investment Partners reports second-quarter portfolio
The firm of Ben Graham-enthusiast Charles Brandes (Trades, Portfolio) announced on Wednesday that it started 13 positions in the second quarter, bringing its complete portfolio to 188 stocks valued around $6.3 billion. Read more...
Amgen Submits Supplemental Biologics License Application For Prolia® (denosumab) In Glucocorticoid-Induced Osteoporosis
Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 980 To US Food And Drug Administration
Amgen Announces 2017 Third Quarter Dividend
FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha® (evolocumab) To Include Data On Reducing Risk Of Cardiovascular Events
Amgen Posts 2nd-Quarter Earnings The health care company beat earnings, revenue expectations
Amgen Inc. (NASDAQ:AMGN) released its second-quarter 2017 financial results on July 25. Read more...
FDA Accepts Amgen's Biologics License Application for Aimovig The target action date is in May 2018
Amgen Inc. (NASDAQ:AMGN) announced July 20 the U.S. Food and Drug Administration will review its Biologics License Application for Aimovig.  Read more...

Ratios

vs
industry
vs
history
PE Ratio 15.22
AMGN's PE Ratio is ranked higher than
78% of the 235 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. AMGN: 15.22 )
Ranked among companies with meaningful PE Ratio only.
AMGN' s PE Ratio Range Over the Past 10 Years
Min: 10.4  Med: 16.1 Max: 30.95
Current: 15.22
10.4
30.95
Forward PE Ratio 13.33
AMGN's Forward PE Ratio is ranked higher than
73% of the 62 Companies
in the Global Biotechnology industry.

( Industry Median: 21.98 vs. AMGN: 13.33 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 15.22
AMGN's PE Ratio without NRI is ranked higher than
80% of the 236 Companies
in the Global Biotechnology industry.

( Industry Median: 31.31 vs. AMGN: 15.22 )
Ranked among companies with meaningful PE Ratio without NRI only.
AMGN' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.4  Med: 16.1 Max: 30.95
Current: 15.22
10.4
30.95
Price-to-Owner-Earnings 13.14
AMGN's Price-to-Owner-Earnings is ranked higher than
76% of the 139 Companies
in the Global Biotechnology industry.

( Industry Median: 34.46 vs. AMGN: 13.14 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
AMGN' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.72  Med: 13.22 Max: 29.05
Current: 13.14
9.72
29.05
PB Ratio 3.86
AMGN's PB Ratio is ranked lower than
51% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. AMGN: 3.86 )
Ranked among companies with meaningful PB Ratio only.
AMGN' s PB Ratio Range Over the Past 10 Years
Min: 1.8  Med: 3.56 Max: 5.02
Current: 3.86
1.8
5.02
PS Ratio 5.40
AMGN's PS Ratio is ranked higher than
69% of the 686 Companies
in the Global Biotechnology industry.

( Industry Median: 12.26 vs. AMGN: 5.40 )
Ranked among companies with meaningful PS Ratio only.
AMGN' s PS Ratio Range Over the Past 10 Years
Min: 3.01  Med: 4.34 Max: 6.64
Current: 5.4
3.01
6.64
Price-to-Free-Cash-Flow 12.79
AMGN's Price-to-Free-Cash-Flow is ranked higher than
75% of the 125 Companies
in the Global Biotechnology industry.

( Industry Median: 28.42 vs. AMGN: 12.79 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AMGN' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 8.79  Med: 12.86 Max: 21.73
Current: 12.79
8.79
21.73
Price-to-Operating-Cash-Flow 11.88
AMGN's Price-to-Operating-Cash-Flow is ranked higher than
77% of the 179 Companies
in the Global Biotechnology industry.

( Industry Median: 25.11 vs. AMGN: 11.88 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AMGN' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.25  Med: 11.58 Max: 17.29
Current: 11.88
7.25
17.29
EV-to-EBIT 11.27
AMGN's EV-to-EBIT is ranked higher than
70% of the 260 Companies
in the Global Biotechnology industry.

( Industry Median: 22.20 vs. AMGN: 11.27 )
Ranked among companies with meaningful EV-to-EBIT only.
AMGN' s EV-to-EBIT Range Over the Past 10 Years
Min: 7.4  Med: 12.9 Max: 22.6
Current: 11.27
7.4
22.6
EV-to-EBITDA 9.38
AMGN's EV-to-EBITDA is ranked higher than
73% of the 278 Companies
in the Global Biotechnology industry.

( Industry Median: 19.37 vs. AMGN: 9.38 )
Ranked among companies with meaningful EV-to-EBITDA only.
AMGN' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.2  Med: 10.4 Max: 18.2
Current: 9.38
6.2
18.2
PEG Ratio 0.75
AMGN's PEG Ratio is ranked higher than
79% of the 102 Companies
in the Global Biotechnology industry.

( Industry Median: 2.10 vs. AMGN: 0.75 )
Ranked among companies with meaningful PEG Ratio only.
AMGN' s PEG Ratio Range Over the Past 10 Years
Min: 0.18  Med: 0.99 Max: 3.03
Current: 0.75
0.18
3.03
Shiller PE Ratio 25.46
AMGN's Shiller PE Ratio is ranked higher than
76% of the 67 Companies
in the Global Biotechnology industry.

( Industry Median: 44.06 vs. AMGN: 25.46 )
Ranked among companies with meaningful Shiller PE Ratio only.
AMGN' s Shiller PE Ratio Range Over the Past 10 Years
Min: 17.36  Med: 26.75 Max: 57.65
Current: 25.46
17.36
57.65
Current Ratio 6.20
AMGN's Current Ratio is ranked higher than
52% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.08 vs. AMGN: 6.20 )
Ranked among companies with meaningful Current Ratio only.
AMGN' s Current Ratio Range Over the Past 10 Years
Min: 1.31  Med: 3.03 Max: 9.3
Current: 6.2
1.31
9.3
Quick Ratio 5.82
AMGN's Quick Ratio is ranked higher than
53% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.79 vs. AMGN: 5.82 )
Ranked among companies with meaningful Quick Ratio only.
AMGN' s Quick Ratio Range Over the Past 10 Years
Min: 1.17  Med: 2.69 Max: 9.22
Current: 5.82
1.17
9.22
Days Inventory 247.16
AMGN's Days Inventory is ranked lower than
79% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 131.43 vs. AMGN: 247.16 )
Ranked among companies with meaningful Days Inventory only.
AMGN' s Days Inventory Range Over the Past 10 Years
Min: 219.41  Med: 300.96 Max: 374.86
Current: 247.16
219.41
374.86
Days Sales Outstanding 56.37
AMGN's Days Sales Outstanding is ranked higher than
62% of the 612 Companies
in the Global Biotechnology industry.

( Industry Median: 65.71 vs. AMGN: 56.37 )
Ranked among companies with meaningful Days Sales Outstanding only.
AMGN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 46.32  Med: 52.25 Max: 67.84
Current: 56.37
46.32
67.84
Days Payable 78.34
AMGN's Days Payable is ranked higher than
64% of the 424 Companies
in the Global Biotechnology industry.

( Industry Median: 54.11 vs. AMGN: 78.34 )
Ranked among companies with meaningful Days Payable only.
AMGN' s Days Payable Range Over the Past 10 Years
Min: 54.15  Med: 84.59 Max: 117.72
Current: 78.34
54.15
117.72

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 2.66
AMGN's Dividend Yield % is ranked higher than
82% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 1.27 vs. AMGN: 2.66 )
Ranked among companies with meaningful Dividend Yield % only.
AMGN' s Dividend Yield % Range Over the Past 10 Years
Min: 0.48  Med: 1.67 Max: 2.8
Current: 2.66
0.48
2.8
Dividend Payout Ratio 0.39
AMGN's Dividend Payout Ratio is ranked higher than
52% of the 131 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. AMGN: 0.39 )
Ranked among companies with meaningful Dividend Payout Ratio only.
AMGN' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.14  Med: 0.32 Max: 0.39
Current: 0.39
0.14
0.39
3-Year Dividend Growth Rate 28.60
AMGN's 3-Year Dividend Growth Rate is ranked higher than
82% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.50 vs. AMGN: 28.60 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
AMGN' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 63.3
Current: 28.6
0
63.3
Forward Dividend Yield % 2.75
AMGN's Forward Dividend Yield % is ranked higher than
84% of the 209 Companies
in the Global Biotechnology industry.

( Industry Median: 1.26 vs. AMGN: 2.75 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 15.68
AMGN's 5-Year Yield-on-Cost % is ranked higher than
97% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 1.54 vs. AMGN: 15.68 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
AMGN' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 2.84  Med: 9.88 Max: 16.57
Current: 15.68
2.84
16.57
3-Year Average Share Buyback Ratio 0.70
AMGN's 3-Year Average Share Buyback Ratio is ranked higher than
97% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. AMGN: 0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AMGN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -10.1  Med: 0.9 Max: 8.7
Current: 0.7
-10.1
8.7

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 211.76
AMGN's Price-to-Net-Current-Asset-Value is ranked lower than
99.99% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: 7.13 vs. AMGN: 211.76 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
AMGN' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 6.7  Med: 24.55 Max: 363.8
Current: 211.76
6.7
363.8
Price-to-Tangible-Book 16.54
AMGN's Price-to-Tangible-Book is ranked lower than
91% of the 797 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. AMGN: 16.54 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AMGN' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.85  Med: 12.22 Max: 150.81
Current: 16.54
3.85
150.81
Price-to-Intrinsic-Value-Projected-FCF 0.92
AMGN's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
89% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 3.53 vs. AMGN: 0.92 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AMGN' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.59  Med: 1.91 Max: 9.49
Current: 0.92
0.59
9.49
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.79
AMGN's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
77% of the 26 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. AMGN: 0.79 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
N/A
Price-to-Median-PS-Value 1.24
AMGN's Price-to-Median-PS-Value is ranked lower than
69% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. AMGN: 1.24 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AMGN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.72  Med: 1.44 Max: 5.17
Current: 1.24
0.72
5.17
Price-to-Peter-Lynch-Fair-Value 0.84
AMGN's Price-to-Peter-Lynch-Fair-Value is ranked higher than
84% of the 76 Companies
in the Global Biotechnology industry.

( Industry Median: 1.95 vs. AMGN: 0.84 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
AMGN' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.58  Med: 1.2 Max: 3.33
Current: 0.84
0.58
3.33
Price-to-Graham-Number 3.34
AMGN's Price-to-Graham-Number is ranked lower than
67% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. AMGN: 3.34 )
Ranked among companies with meaningful Price-to-Graham-Number only.
AMGN' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.52  Med: 3.74 Max: 23.03
Current: 3.34
1.52
23.03
Earnings Yield (Greenblatt) % 8.87
AMGN's Earnings Yield (Greenblatt) % is ranked higher than
92% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: -8.14 vs. AMGN: 8.87 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AMGN' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.4  Med: 7.8 Max: 13.6
Current: 8.87
4.4
13.6
Forward Rate of Return (Yacktman) % 24.18
AMGN's Forward Rate of Return (Yacktman) % is ranked higher than
71% of the 129 Companies
in the Global Biotechnology industry.

( Industry Median: 14.33 vs. AMGN: 24.18 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AMGN' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 3  Med: 20.2 Max: 95.7
Current: 24.18
3
95.7

More Statistics

Revenue (TTM) (Mil) $23,050.00
EPS (TTM) $ 10.99
Beta1.83
Short Percentage of Float1.06%
52-Week Range $133.64 - 184.21
Shares Outstanding (Mil)729.67

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 22,882 23,052 23,116
EPS ($) 12.34 12.87 13.00
EPS without NRI ($) 12.34 12.87 13.00
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.19%
Dividends per Share ($) 4.62 5.16 5.62
» More Articles for AMGN

Headlines

Articles On GuruFocus.com
Graham-Disciple Charles Brandes' 5 Largest 2nd Quarter New Buys Aug 09 2017 
Amgen Submits Supplemental Biologics License Application For Prolia® (denosumab) In Glucocorticoid- Jul 31 2017 
Amgen And Allergan Submit Biosimilar Biologics License Application For ABP 980 To US Food And Drug A Jul 31 2017 
Amgen Announces 2017 Third Quarter Dividend Jul 28 2017 
FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For Repatha® (evo Jul 27 2017 
Amgen Posts 2nd-Quarter Earnings Jul 26 2017 
FDA Accepts Amgen's Biologics License Application for Aimovig Jul 21 2017 
FDA Accepts Biologics License Application For Aimovig™ (erenumab) Jul 20 2017 
Amgen Announces Webcast of 2017 Second Quarter Financial Results Jul 20 2017 
Amgen And Array BioPharma Announce Preclinical License And Collaboration Agreement In Inflammation Jul 18 2017 

More From Other Websites
Amgen in Collaboration With Humana for Patients' Benefit Aug 18 2017
Is Regeneron Pharmaceuticals the Best Biotech Stock to Buy? Aug 17 2017
Amgen And Humana Partner For Improved Health Outcomes And Efficiency Aug 17 2017
Where Amgen’s Enbrel and Nplate Stand after 2Q17 Aug 17 2017
See what the IHS Markit Score report has to say about Amgen Inc. Aug 17 2017
How Amgen’s Nephrology Drugs Are Positioned after 2Q17? Aug 17 2017
Repatha® (Evolocumab) Phase 3 Cognitive Function Study Results Published In The New England Journal... Aug 16 2017
What We May See from Amgen’s Vectibix in 2017 Aug 16 2017
Biogen: Goldman Has Conviction! Aug 16 2017
What Amgen Expects from Blincyto in 2017 Aug 16 2017
How Amgen’s Repatha Performed in 2Q17 Aug 15 2017
Can Ligand's Captisol Deals Boost Growth in the Long Run? Aug 15 2017
Gauging Amgen’s Xgeva Contribution in 2017 Aug 15 2017
Are Amgen's New Drugs Doing Well Enough to Drive Sales? Aug 15 2017
What Kyprolis Could Do for Amgen’s Revenue Growth Aug 15 2017
Behind Amgen’s High Revenue Growth from Prolia in 2Q17 Aug 14 2017
Inside Amgen’s 2Q17 Performance Aug 14 2017
What Amgen’s Analysts Recommend in August 2017 Aug 14 2017
The Zacks Analyst Blog Highlights: Disney, Amgen, Caterpillar, S&P Global and Emerson Electric Aug 14 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}